Tenaya Therapeutics Stock Forecast

Sell candidate since Jun 22, 2026 Gain 1.43%

The Tenaya Therapeutics, Inc. stock price fell by -2.86% on the last day (Thursday, 25th Jun 2026) from $0.731 to $0.710. During the last trading day the stock fluctuated 5.35% from a day low at $0.710 to a day high of $0.748. The price has risen in 6 of the last 10 days and is up by 1.68% over the past 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -536 thousand shares and in total, 1 million shares were bought and sold for approximately $913.79 thousand.

The stock lies in the lower part of a very wide and weak rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $0.686 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 6.03% during the next 3 months and, with a 90% probability hold a price between $0.727 and $1.09 at the end of this 3-month period.

TNYA Signals & Forecast

There are mixed signals in the stock today. The Tenaya Therapeutics, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.713 and $0.793. A break-up above any of these levels will issue buy signals. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk. A buy signal was issued from a pivot bottom point on Tuesday, June 16, 2026, and so far it has risen 4.41%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Tenaya Therapeutics, Inc. stock

Tenaya Therapeutics, Inc. finds support from accumulated volume at $0.700 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0380 between high and low, or 5.35%. For the last week the stock has had daily average volatility of 6.58%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (TNYA) For The Upcoming Trading Day Of Friday 26th

For the upcoming trading day on Friday, 26th we expect Tenaya Therapeutics, Inc. to open at $0.723, and during the day (based on 14 day Average True Range), to move between $0.682 and $0.738, which gives a possible trading interval of +/-$0.0557 (+/-8.17%) up or down from last closing price. If Tenaya Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 8.17% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $0.700 (1.41%) than the resistance at $0.783 (10.28%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Tenaya Therapeutics, Inc. stock A Buy?

Tenaya Therapeutics, Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -2.098 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on June 26, 2026 - $0.723 ( 1.78%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk